Since the end of 2009, XuanZhu Pharma has successively submitted IND filings for 11 Category 1.1 innovative drugs, including anti-infective drugs Apapenem and Benapenem; anti-acid drug Anaprazole Sodium, anti-diabetic drug Imigliptin Hydrochloride and anti-hypertensive drug Tylerdipine Hydrochloride.

August, 2016
CFDA Granted Approval of Phase II/III Clinical Trials for Imigliptin Hydrochloride,a category 1.1 antidiabetic drug
August, 2015
CFDA granted IND applications to Pirotinib Hydrochloride, a category 1.1 anti-oncology drug
June, 2015
IND of National Category 1.1 anti-cancer new drug Sirotinib is approved by CFDA
April, 2015
First Patient In is achieved for Pirotinib in Phase I trial in the United States
March, 2015
Benapenem, a National Category 1.1 injectable antibiotic, is tested in human for the first time. It is well tolerated in subjects
December, 2014
Imigliptin Hydrochloride, a National Category 1.1 anti-hypertensive new drug, is tested in human for the first time. It is well tolerated in subjects
November, 2014
The IND filing of national Category 1.1 anti-oncology innovative patent drug Pirotinib Hydrochloride is approved by FDA for clinical studies
October, 2014
The IND filing of national Category 1.1 anti-oncology innovative patent drug Pirotinib Hydrochloride is submitted to FDA
September, 2014
The national Category 1.1 anti-hypertensive new drug Tylerdipine Hydrochloride is approved by CFDA for clinical trials as Category One new drug
June, 2013
The national Category 1.1 anti-acid drug Anaprazole Sodium is approved by CFDA for clinical trials as Category One new drug
February, 2013
The national Category 1.1 anti-diabetic drug Imigliptin Hydrochloride is approved by CFDA for clinical trials as Category One new drug and is ready for phase I clinical experiments
January, 2013
The national Category 1.1 antibiotic new drug Benapenem has been approved by CFDA for clinical trials as Category One new drug and is ready for phase I clinical experiments
December, 2012
The IND filing of national Category 1.1 anti-hypertensive new drug Tylerdipine Hydrochloride is submitted to SFDA
December, 2011
The national Category 1.1 antibiotic new drug Apapenem is approved by CFDA for clinical trials as Category One new drug
 

Email | Terms of Use | Contact us

2014版權?軒竹醫藥科技有限公司保留所有權利 魯ICP備09030169號

圣盛湖北公安晃晃麻将 安徽快3推荐号一定牛 怎样在网上兼职赚钱 福州麻将手机版下载 幸运农场中八个多少钱 平特一肖一尾什么意思 *明天股票涨停 在家做什么网上兼职 北方推倒胡规则 亿胜金融 湖北十一选五预测号码